Adaptive RSK‐EphA2‐GPRC5A signaling switch triggers chemotherapy resistance in ovarian cancer
2020 · EMBO Molecular Medicine · 71 citations
https://doi.org/10.15252/emmm.201911177
S
Sara Corvigno
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
76
Papers
1.0K
Citations
17
h-index
25
i10-index
Sara Corvigno is an academic researcher from The University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Ovarian cancer diagnosis and treatment & Cancer Genomics and Diagnostics & Cancer Cells and Metastasis. The author has an h-index of 17, co-authored 65 publications.
ORCID: 0000-0001-5458-2243Papers by this author
worksTumor core biopsies adequately represent immune microenvironment of high-grade serous carcinoma
2019 · Scientific Reports · 28 citations
https://doi.org/10.1038/s41598-019-53872-1
Prognostic Interactions between FAP+ Fibroblasts and CD8a+ T Cells in Colon Cancer
2020 · Cancers · 21 citations
https://doi.org/10.3390/cancers12113238
Targeting CCR2+ macrophages with BET inhibitor overcomes adaptive resistance to anti-VEGF therapy in ovarian cancer
2022 · Journal of Cancer Research and Clinical Oncology · 15 citations
https://doi.org/10.1007/s00432-021-03885-z
High prevalence of FAP+ cancer-associated fibroblasts predicts poor outcome in patients with high-grade serous ovarian cancer with high CD8 T-cell density
2025 · Gynecologic Oncology · 9 citations
https://doi.org/10.1016/j.ygyno.2025.01.010
Endothelial p130cas confers resistance to anti-angiogenesis therapy
2022 · Cell Reports · 8 citations
https://doi.org/10.1016/j.celrep.2022.110301
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat